nascobal (r) (b 12) demand is strong

Quote
























I checked and yes detroit's performance is exemplary. Nascobal sales are in fact trending nicely for par and results from detroit are NO different. The disgruntled employee is well known and within sights. Good news coming on wednesday


(((((((((REMEMBER $40)))))))))))
 






Mr P Cos told us 2 years ago the below FAVORABLE metrics

The right prescription
Generic drug maker Par Pharmaceuticals saw revenue nearly double year over year in its latest quarter. More than half of Par's $295 million revenue came from metoprolol, the authorized generic for AstraZeneca's Toprol XL. The company also launched several new drugs to help bolster operations, and with more to come, investors could see valuations rise.

Highly rated CAPS All-Star member IBDvalueinvestin is impressed not only with Par's current portfolio of drugs, but also its pipeline:

[Par is] looking to get approvals on an additional $6.5B worth of drugs. [Par's] Total revenue nearly doubled to $294.8 million

Analysts on average expected earnings of 49 cents a share on revenue of $290.4 million, according to Thomson Reuters....

[Par] said it currently has about 27 abbreviated new drug applications pending with the U.S. health regulators, 13 of which the company believes have first-to-file or first-to-market opportunities with a brand value of about $6.5 billion.

At less than one times sales, Par Pharmaceuticals carries a far larger discount than either Teva Pharmaceuticals (Nasdaq: TEVA) or Mylan (NYSE: MYL) and is smaller than either. Yet analysts are expecting Par's average annual growth over five years to far outstrip that of its larger rivals. With about half as many Wall Street types tracking the generic drug specialist, Par looks like an underfollowed star ready to break out.

Use the comments section below to let us know if you consider the drug maker to be a generic opportunity, or head over to Par Pharmaceuticals' CAPS page and tell us your prescription for success.

Foolish final thoughts
Academics will tell you that individual investors have little chance of beating the stock market. They say the Warren Buffetts, Shelby Davises, and Peter Lynches are the exceptions to the rule. We at The Motley Fool don't agree. Stock investing is not brain surgery. Finding good, undervalued companies is not as difficult as the professionals want you to think.

It is possible to make a more comfortable retirement for yourself, even if you have little money to start with or are starting late in life. It is possible to turn $100 into $1 million. You just have to commit: Do it now, and do it regularly. No amount is too small. Let's get started. There's no time to lose!

“The Next Great Investment”… That’s how a top global investor describes India’s potential. On Nov. 28, The Motley Fool’s Tim Hanson returns to India to prove it. Follow along in real time and get his TOP pick first (Hanson returned from China in July with a stock that’s up 169%!). Enter email below.
 






THE P COMPANIES said:
I checked and yes detroit's performance is exemplary. Nascobal sales are in fact trending nicely for par and results from detroit are NO different. The disgruntled employee is well known and within sights. Good news coming on wednesday


(((((((((REMEMBER $40)))))))))))
Click to expand...

10/23/09 10/30/09 11/6/09 11/13/09
Nascobal TRx 1,499 1,563 1,375 1,348


Do the math. Nascobal Rxs going down.................
 






Anonymous said:
Mr P Cos told us 2 years ago the below FAVORABLE metrics

The right prescription
Generic drug maker Par Pharmaceuticals saw revenue nearly double year over year in its latest quarter. More than half of Par's $295 million revenue came from metoprolol, the authorized generic for AstraZeneca's Toprol XL. The company also launched several new drugs to help bolster operations, and with more to come, investors could see valuations rise.

Highly rated CAPS All-Star member IBDvalueinvestin is impressed not only with Par's current portfolio of drugs, but also its pipeline:

[Par is] looking to get approvals on an additional $6.5B worth of drugs. [Par's] Total revenue nearly doubled to $294.8 million

Analysts on average expected earnings of 49 cents a share on revenue of $290.4 million, according to Thomson Reuters....

[Par] said it currently has about 27 abbreviated new drug applications pending with the U.S. health regulators, 13 of which the company believes have first-to-file or first-to-market opportunities with a brand value of about $6.5 billion.

At less than one times sales, Par Pharmaceuticals carries a far larger discount than either Teva Pharmaceuticals (Nasdaq: TEVA) or Mylan (NYSE: MYL) and is smaller than either. Yet analysts are expecting Par's average annual growth over five years to far outstrip that of its larger rivals. With about half as many Wall Street types tracking the generic drug specialist, Par looks like an underfollowed star ready to break out.

Use the comments section below to let us know if you consider the drug maker to be a generic opportunity, or head over to Par Pharmaceuticals' CAPS page and tell us your prescription for success.

Foolish final thoughts
Academics will tell you that individual investors have little chance of beating the stock market. They say the Warren Buffetts, Shelby Davises, and Peter Lynches are the exceptions to the rule. We at The Motley Fool don't agree. Stock investing is not brain surgery. Finding good, undervalued companies is not as difficult as the professionals want you to think.

It is possible to make a more comfortable retirement for yourself, even if you have little money to start with or are starting late in life. It is possible to turn $100 into $1 million. You just have to commit: Do it now, and do it regularly. No amount is too small. Let's get started. There's no time to lose!

“The Next Great Investment”… That’s how a top global investor describes India’s potential. On Nov. 28, The Motley Fool’s Tim Hanson returns to India to prove it. Follow along in real time and get his TOP pick first (Hanson returned from China in July with a stock that’s up 169%!). Enter email below.
Click to expand...



thank you yes it took the WS experts 2 years and some still do not get it!
 






nascobal doing well and watson is still waiting and waiting for fda approval for other toprol mgs and waiting


par owned toprol market in q4 and this continues into q1


$$$$$$$$$$$$$$FORTY$$$$$$$$$$
 






























$$$$$$ EUPHORIA COMING $$$$$$$ 10 second(s) ago HOW DO YOU GET THOSE CUTTING EDGE INSIGHTFUL MAJOR NEWS LEAKS?


Yesterday, 07:54 PM
Anonymous Posts: n/a

Re: nascobal (r) (b 12) demand is strong

----------------------------------------------------- ---------------------------
euphoria coming

Sentiment : Strong Buy
 






Re: BLACK ROCK BUILDS A 9% STAKE 31-Jan-10 05:16 pm (1)Names of reporting persons. BlackRock, Inc.

This Amendment to Schedule 13G (this "Amendment")
is filed by BlackRock, Inc. ("BlackRock"). It amends
the most recent Schedule 13G filing, if any, made by
BlackRock and the most recent Schedule 13G filing,
if any, made by Barclays Global Investors, NA and
certain of its affiliates (Barclays Global Investors, NA
and such affiliates are collectively referred to as the
"BGI Entities") with respect to the subject class
of securities of the above-named issuer. As previously
announced, on December 1, 2009 BlackRock
completed its acquisition of Barclays Global Investors
from Barclays Bank PLC. As a result, [substantially all of]
the BGI Entities are now included as subsidiaries of
BlackRock for purposes of Schedule 13G filings.


(2) Check the appropriate box if a member of a group
(a)
(b)

(3) SEC use only

(4) Citizenship or place of organization

Delaware

Number of shares beneficially owned by each reporting person with:

(5)Sole voting power

3128226

(6)Shared voting power

None

(7)Sole dispositive power

3128226

(8)Shared dispositive power

None

(9)Aggregate amount beneficially owned by each reporting person

3128226

(10)Check if the aggregate amount in Row (9) excludes certain shares

(11)Percent of class represented by amount in Row 9

8.98%

(12)Type of reporting person

HC

Sentiment : Strong Buy
Rating :
(No ratings)
 












A DAY LATE BUT SPOT ON


((((((((((BUY WITH BOTH FISTS ALERT))))))) 1 minute ago NO REASON FOR SELLOFF

SIMPLY PUT A FALSE ALARM

sure there is a delay for zup but launch still probable in summer

actually nascobal did 1458 new scripts just out per ims

NASCOBAL DOING BETTER THEN EXPECTED


ON TRACK TO YES

$$$$$$$$$$FORTY$$$$$$$$$$$$$

Sentiment : Strong Buy
Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse
 






Anonymous said:
A DAY LATE BUT SPOT ON


((((((((((BUY WITH BOTH FISTS ALERT))))))) 1 minute ago NO REASON FOR SELLOFF

SIMPLY PUT A FALSE ALARM

sure there is a delay for zup but launch still probable in summer

actually nascobal did 1458 new scripts just out per ims

NASCOBAL DOING BETTER THEN EXPECTED


ON TRACK TO YES

$$$$$$$$$$FORTY$$$$$$$$$$$$$

Sentiment : Strong Buy
Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse
Click to expand...


NICE JOB BRANDED


watson delay/ PAR GAIN 26 second(s) ago We all know toprol generic is difficult very difficult to manufacture

kv is living proof

Obvioulsy watson is having problems getting the fda to approve the additional more commonly used higher strengths of metoprolol

GOOD NEWS VERY GOOD NEWS FOR PRX AS wpi expected the approvals in nov 2009


is it

$$$$$$$$$$$$$$$$$FORTY$$$$$$$$$$$$$$


OR

$$$$$$$$$$$$$$$$$FIFTY$$$$$$$$$$$$$$$
wpi source told me so back about 3 months ago

Sentiment : Strong Buy
 






nice call


Anonymous said:
A DAY LATE BUT SPOT ON


((((((((((BUY WITH BOTH FISTS ALERT))))))) 1 minute ago NO REASON FOR SELLOFF

SIMPLY PUT A FALSE ALARM

sure there is a delay for zup but launch still probable in summer

actually nascobal did 1458 new scripts just out per ims

NASCOBAL DOING BETTER THEN EXPECTED


ON TRACK TO YES

$$$$$$$$$$FORTY$$$$$$$$$$$$$

Sentiment : Strong Buy
Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse
Click to expand...
 












Top Bottom
Back
Quote